Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire,
CT 06410
United States - Map
Phone: 203-272-2596
Fax: 203-271-8198
Web Site: http://www.alexionpharm.com
| Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers. Alexion PharmaceuticalsÂ’ drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors. Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Leonard Bell M.D., 50
Co-Founder, Chief Exec. Officer, Sec., Treasurer |
$
1.37M |
$
2.18M | Dr. Stephen P. Squinto Ph.D., 53
Co-Founder, Exec. VP and Head of R&D |
$
575.00K |
$
1.87M | Dr. Joseph A. Madri Ph.D., M.D., 63
Founder, Independent Director, Member of Compensation Committee and Member of Compliance & Quality Committee |
$
62.00K | N/A | Mr. Vikas Sinha M.B.A., C.A., 46
Chief Financial Officer and Sr. VP |
$
591.00K |
$
647.00K | Dr. Thomas I. H. Dubin J.D., 47
Sr. VP and Gen. Counsel |
$
614.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
